Back to Browse Journals » Nature and Science of Sleep » Volume 4

Shift work: health, performance and safety problems, traditional countermeasures, and innovative management strategies to reduce circadian misalignment

Authors Smith MR, Eastman CI

Published Date September 2012 Volume 2012:4 Pages 111—132

DOI http://dx.doi.org/10.2147/NSS.S10372

Received 13 July 2012, Accepted 21 August 2012, Published 27 September 2012

Mark R Smith, Charmane I Eastman

Biological Rhythms Research Laboratory, Rush University Medical Center, Chicago, IL, USA

Abstract: There are three mechanisms that may contribute to the health, performance, and safety problems associated with night-shift work: (1) circadian misalignment between the internal circadian clock and activities such as work, sleep, and eating, (2) chronic, partial sleep deprivation, and (3) melatonin suppression by light at night. The typical countermeasures, such as caffeine, naps, and melatonin (for its sleep-promoting effect), along with education about sleep and circadian rhythms, are the components of most fatigue risk-management plans. We contend that these, while better than nothing, are not enough because they do not address the underlying cause of the problems, which is circadian misalignment. We explain how to reset (phase-shift) the circadian clock to partially align with the night-work, day-sleep schedule, and thus reduce circadian misalignment while preserving sleep and functioning on days off. This involves controlling light and dark using outdoor light exposure, sunglasses, sleep in the dark, and a little bright light during night work. We present a diagram of a sleep-and-light schedule to reduce circadian misalignment in permanent night work, or a rotation between evenings and nights, and give practical advice on how to implement this type of plan.

Keywords: circadian rhythms, night work, bright light, phase-shifting, sleep, melatonin

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Nanomedicine strategies for treatment of secondary spinal cord injury

White-Schenk D, Shi R, Leary JF

International Journal of Nanomedicine 2015, 10:923-938

Published Date: 29 January 2015

Optimal management of breast cancer in the elderly patient: current perspectives

Le Saux O, Ripamonti B, Bruyas A, Bonin O, Freyer G, Bonnefoy M, Falandry C

Clinical Interventions in Aging 2015, 10:157-174

Published Date: 6 January 2015

The Western Denmark Cardiac Computed Tomography Registry: a review and validation study

Nielsen LH, Nørgaard BL, Tilsted HH, Sand NP, Jensen JM, Bøttcher M, Diederichsen AC, Lambrechtsen J, Kristensen LD, Mickley H, Munkholm H, Gøtzsche O, Knudsen LL, Bøtker HE, Pedersen L, Schmidt M

Clinical Epidemiology 2015, 7:53-64

Published Date: 31 December 2014

Photothermal cancer therapy using graphitic carbon–coated magnetic particles prepared by one-pot synthesis

Lee HJ, Sanetuntikul J, Choi ES, Lee BR, Kim JH, Kim E, Shanmugam S

International Journal of Nanomedicine 2015, 10:271-282

Published Date: 30 December 2014

Melanocytoma of the ciliary body misdiagnosed as iridodialysis

Kim M, Lee SJ

Clinical Ophthalmology 2014, 8:1051-1053

Published Date: 29 May 2014

Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4

Shiozaki Y, Kitajima T, Mazaki T, Yoshida A, Tanaka M, Umezawa A, Nakamura M, Yoshida Y, Ito Y, Ozaki T, Matsukawa A

International Journal of Nanomedicine 2013, 8:1349-1360

Published Date: 9 April 2013

Hepatocyte-targeting gene transfer mediated by galactosylated poly(ethylene glycol)- graft-polyethylenimine derivative

Wang YQ, Su J, Cai WW, Lu P, Yuan LF, Jin T, Chen SY, Sheng J

Drug Design, Development and Therapy 2013, 7:211-221

Published Date: 26 March 2013

Medical device vigilance systems: India, US, UK, and Australia

Pooja Gupta, Manthan D Janodia, Puralea C Jagadish, et al

Medical Devices: Evidence and Research 2010, 3:67-79

Published Date: 22 November 2010